Viewing Study NCT04167540



Ignite Creation Date: 2024-05-06 @ 1:56 PM
Last Modification Date: 2024-10-26 @ 1:22 PM
Study NCT ID: NCT04167540
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2023-01-19
First Post: 2019-11-07

Brief Title: GDNF Gene Therapy for Parkinsons Disease
Sponsor: Brain Neurotherapy Bio Inc
Organization: Brain Neurotherapy Bio Inc

Study Overview

Official Title: Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer AAV2- GDNF in Parkinsons Disease
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None